Abcam Shareholders Approve Proposed Acquisition By Danaher
$ABCM
$DHR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Industrial Machinery/Components
Industrials
Abcam Shareholders Approve Proposed Acquisition By Danaher
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/9/2025 | $265.00 | Buy | Goldman | |
| 12/2/2025 | $270.00 | Overweight | Morgan Stanley | |
| 10/8/2025 | $220.00 | Buy → Neutral | Rothschild & Co Redburn | |
| 7/11/2025 | $275.00 | Sector Perform → Sector Outperform | Scotiabank | |
| 4/10/2025 | $205.00 | Equal Weight → Overweight | Barclays | |
| 3/21/2025 | $260.00 | Neutral → Buy | Goldman | |
| 3/14/2025 | $260.00 | Hold → Buy | Stifel | |
| 2/3/2025 | Outperform → Mkt Perform | Raymond James |
WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €500,000,000 principal amount of floating rate senior notes due 2028 at an offering price of 100.000% of the principal amount;€750,000,000 principal amount of 3.250% senior notes due 2030 at an offering price of 99.934% of the principal amount;€750,000,000 principal amount of 3.625% senior notes due 2034 at an offering price of 99.918% of the principal amount; and€1,000,000,000 principal amount of 4.000% senior notes due 2038 at an offering price of 99.953% of the principal amount (collectively, t
WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key First Quarter 2026 ResultsNet earnings were $1.0 billion, or $1.45 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 9.5% to $2.06.Revenues increased 3.5% year-over-year to $6.0 billion and non-GAAP core revenue increased 0.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Strong Q1 earnings performance enabling increased full year 2026 adju
Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing BREA, Calif., April 13, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes. Validated for use
Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00
Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00
Rothschild & Co Redburn downgraded Danaher from Buy to Neutral and set a new price target of $220.00
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
424B5 - DANAHER CORP /DE/ (0000313616) (Filer)
FWP - DANAHER CORP /DE/ (0000313616) (Subject)
424B5 - DANAHER CORP /DE/ (0000313616) (Filer)
SC 13G/A - Abcam plc (0001492074) (Subject)
SC 13G/A - Abcam plc (0001492074) (Subject)
SC 13D/A - Abcam plc (0001492074) (Subject)
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2
Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective
WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca
WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key First Quarter 2026 ResultsNet earnings were $1.0 billion, or $1.45 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 9.5% to $2.06.Revenues increased 3.5% year-over-year to $6.0 billion and non-GAAP core revenue increased 0.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Strong Q1 earnings performance enabling increased full year 2026 adju
WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You ca
WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and